npj Precision Oncology (Mar 2022)

Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors

  • Enrico Berrino,
  • Roberto Filippi,
  • Clara Visintin,
  • Serena Peirone,
  • Elisabetta Fenocchio,
  • Giovanni Farinea,
  • Franco Veglio,
  • Massimo Aglietta,
  • Anna Sapino,
  • Matteo Cereda,
  • Rosella Visintin,
  • Barbara Pasini,
  • Caterina Marchiò

DOI
https://doi.org/10.1038/s41698-022-00258-8
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 9

Abstract

Read online

Abstract The onset of multiple and metachronous tumors in young patients induces to suspect the presence of genetic variants in genes associated with tumorigenesis. We describe here the unusual case of a 16-year-old patient who developed a synchronous bifocal colorectal adenocarcinoma with distant metastases. We provide high throughput molecular characterization with whole-exome sequencing (WES) and DNA targeted sequencing of different tumoral lesions and normal tissue samples that led to unveil a germline POLE mutation (p.Ser297Cys) coexisting with the PMS2 c.2174 + 1 G > A splicing mutation. This clinical scenario defines a “POLE-LYNCH” collision syndrome, which explains the ultra-mutator phenotype observed in the tumor lesions, and the presence of MMR deficiency-associated unusual signatures. The patient was successfully treated with immune checkpoint inhibitors but subsequently developed a high-grade urothelial carcinoma cured by surgery. We complement this analysis with a transcriptomic characterization of tumoral lesions with a panel targeting 770 genes related to the tumor microenvironment and immune evasion thus getting insight on cancer progression and response to immunotherapy.